T-VEC had been firstly tested in a Phase I study, where it demonstrated biological activity in terms of active viral replication, local reactions (erythema and inflammation of the injected lesions), granulocyte-macrophage colony stimulating factor (GMCSF) expression, tumor necrosis and apoptosis, as evaluated in post-treatment biopsies. This evidence concerns the gene CSF2 and Erythema.